罗格列酮对2型糖尿病患者血浆vaspin水平影响的研究

摘要

Objective To investigate the effect of rosiglitazone therapy on plasma vaspin in T2DM patients inadequately controlled on metformin alone. Methods A total of 105 subjects, including 37 subjects with NGT, 37 subjects with IGR, and 31 T2DM patients with poor glycemic control on metformin alone, were enrolled in this study. The T2DM patients were treated with rosiglitazone for 12 weeks. The somatometric parameters and the needed biochemical indices were determined. The homeostasis model assessment (HOMA) was adopted to evaluate the insulin resistance (IR) and islet β cell function index (IS). ELISA was used to determine the plasma vaspin concentration. An analysis of the correlation between vaspin concentration and all parameters was carried out and the changes in vaspin concentration after the rosiglitazone treatment were observed. Results Fasting plasma vaspin level was higher in the T2DM patients with poor glycemic control than in the IGR and NGT groups [(1.19±0. 74) μg/L vs (0.46±0.26)μg/L vs (0. 54±0.28)μg/L, P<0.05], but no difference between IGR and NGT groups. In the T2DM patients, fasting plasma vaspin concentration was significantly decreased after rosiglizatone therapy for 12 weeks [(1.19±0. 74)μg/L vs (0.91±0. 54)μg/L,P<0.05], accompanied with significant amelioration of insulin sensitivity and glucose control. Plasma vaspin levels were positively associated with the FIns and HOMA-IR. Conclusion Plasma vaspin level is higher in T2DM patients with poor glycemic control. And rosiglitazone therapy decreases plasma vaspin level through glucose and insulin sensitivity regulation.u0000levels wer%目的 探讨罗格列酮对T2DM患者血浆内脏脂肪特异性丝氨酸蛋白酶抑制剂(vaspin)水平的影响. 方法 将105例研究对象分为NGT、IGR和T2DM组.T2DM组用罗格列酮治疗12周.检测人体测量参数和生化指标,采用稳态模型评估胰岛素抵抗指数(HOMA-IR)及胰岛β细胞功能指数(HOMA-IS),用ELISA测定血浆vaspin浓度.分析vaspin浓度及各参数间的关系及罗格列酮治疗前后vaspin浓度的变化. 结果 T2DM组空腹血浆vaspin水平(1.19±0.74)μg/L高于NGT组(0.54±0.28)μg/L和IGR组(0.46±0.26)μg/L(P＜0.05),NGT组和IGR组间差异无统计学意义.血浆vaspin水平与FIns和HOMA-IR呈正相关.罗格列酮治疗12周后,T2DM组空腹血浆vaspin水平明显下降[(1.19±0.74)μg/Lvs(0.91±0.54)μg/L,P＜0.05]. 结论 T2DM组血浆vaspin水平增高,罗格列酮治疗在控制血糖及改善IS同时,降低了血浆vaspin水平.